New Era in Alzheimer's Diagnosis: Blood Tests to Revolutionize Early Detection

BGI Genomics, Roche Diagnostics, and Fujirebio Holdings are launching new tests for Alzheimer's in China, improving diagnosis and treatment accessibility. These blood tests aim to make the diagnostic process faster and less invasive, facilitating early detection while offering patients more comfortable alternatives to traditional methods.

BGI Genomics and Roche Diagnostics have introduced new Alzheimer's tests in China, aiming to make diagnosis and monitoring more accessible for patients with the neurodegenerative condition.

BGI is utilizing a blood test as a supportive tool across multiple Chinese cities, while Roche is working on regulatory approval for its pTau181 test in Hainan.

Fujirebio Holdings also plans to launch a test kit in China, aiming to provide quicker diagnostics and easier treatment access than traditional methods like spinal taps or PET scans.

(With inputs from agencies.)